SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 47.21 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 5.98 |
| Book Value / Share | 0.08 |
| Price / Book | n/a |
| NCAV ($M) | 4.67 |
| NCAV / Share | 0.06 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -4.50 |
| Return on Assets (ROA) | -0.82 |
| Return on Equity (ROE) | -1.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 2.82 |
| Current Ratio | 2.82 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 18.88 |
| Assets | 20.19 |
| Liabilities | 14.20 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -34.98 |
| Net Income | -31.71 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -26.97 |
| Cash from Investing | -0.24 |
| Cash from Financing | 6.64 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Anson Funds Management LP | 9.60 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 67,272 | 207,111 | 32.48 | |
| 200,735 | 683,116 | 29.39 | |
| 125,657 | 279,025 | 45.03 | |
| 150,822 | 350,217 | 43.07 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| OCX – OncoCyte Corporation | OKYO – OKYO Pharma Limited |
| ONCO – Onconetix, Inc. | ONVO – Organovo Holdings, Inc. |
| ORGO – Organogenesis Holdings Inc. |
Financial data and stock pages provided by
Fintel.io